COUR Pharmaceutical

US-based COUR Pharmaceutical has announced a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize COUR’s proprietary tolerogenic nanoparticle treatments aimed at addressing an autoimmune disease. Financial Terms and Milestones of the AgreementAccording to the agreement, COUR is set to receive upfront…